Skip to content

Inspection Record

Cook Pharmica LLC — FDA 483 Findings

US FDAInspected 2018-05-01Published 2018-09-10 5 findingsContamination controlComputer system validationOther quality systemDeviation, CAPA, and investigation

View the regulator's official source The source document is always the basis for judgement.

Findings

2Computer system validation

Sufficient controls to prevent unauthorized changes to data stored on your firm’s HPLC and GC ' |computer systems are inadequate.

3Other quality system

There is a lack ofquality oversight in the review ofrecords and procedures followed indrug substance manufacture.

4Deviation, CAPA, and investigation

Corrective actions do not include implementation ofadequate procedures to prevent similar — deviations from recurring.

5Other quality system

There is an unacceptably high number ofmold recoveries in the classified rooms used for manufacture of bulk drug substance.

A record as of the US FDA document published on 2018-09-10. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Cook Pharmica LLC company profile — full historyAll US FDA findings US FDA documents, 2018 Go to Findings search
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.